Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide

Tarang Sharma, Maday Galeana Figueroa, Ravi Shah, Meera Mohan, Parameswaran Hari, Sabarinath Radhakrishnan

Blood (2025) 146 (Supplement 1): 4108.

https://doi.org/10.1182/blood-2025-4108

Published: 2025

Journal Articles

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag, Mansi Shah, Sabarinath Radhakrishnan, Binod Dhakal, Samer Al Hadidi, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2025) 146 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2025-2226

Published: 2025

Journal Articles

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Binod Dhakal, Maria Hintzke, Othman Akhtar, Jamila Mammadova, Adetola Kassim, Marcelo Pasquini, Meera Mohan, Ravi Kishore Narra, Sabarinath Radhakrishnan, Fumou Sun, Anita D'Souza, Maher Albitar, Bhagirathbhai Dholaria

Blood (2025) 146 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2025-2240

Published: 2025

Journal Articles

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson, Ravi Kishore Narra, Othman Akhtar, Sabarinath Radhakrishnan, Marcelo Pasquini, Binod Dhakal, Anita D'Souza, Meera Mohan

Blood (2025) 146 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2025-2800

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin, Temitope Oloyede, Ravi Narra, Sabarinath Radhakrishnan, Meera Mohan, Binod Dhakal, Marcelo Pasquini, Anita D'Souza, Othman Akhtar

Blood (2025) 146 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2025-6360

Published: 2025

Journal Articles

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Radhakrishnan, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Meera Mohan

Blood (2023) 142 (Supplement 1): 358.

https://doi.org/10.1182/blood-2023-182695

Published: 2023

Journal Articles

Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy

Blood (2022) 140 (Supplement 1): 8038–8039.

https://doi.org/10.1182/blood-2022-168794

Published: 2022

Journal Articles

Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Lindsay Hammons, Shabi Haider, Marcelo C Pasquini, Saurabh Chhabra, Sabarinath Radhakrishnan, Anthony E. Zamora, Meera Mohan, Jing Dong, Siegfried Janz, Anita D'Souza, Parameswaran Hari, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7215–7216.

https://doi.org/10.1182/blood-2022-165483

Published: 2022

Journal Articles

Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study

Meera Mohan, Nathaniel Verhagen, Aditya Shreenivas, Sabarinath Radhakrishnan, Binod Dhakal, Saurabh Chhabra, Michael A. Thompson, Marcelo C Pasquini, Anita D'Souza, Mehdi Hamadani, Aniko Szabo, Anai Kothari

Blood (2022) 140 (Supplement 1): 940–941.

https://doi.org/10.1182/blood-2022-165413

Published: 2022

Journal Articles

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

Michael Olson, Tim Luetkens, Fiorella Iglesias, Sabarinath Radhakrishnan, Jennie Y. Law, Stephanie Avila, Erica Vander Mause, Nicola J Camp, Erin Morales, Aaron P. Rapoport, Saurabh Dahiya, Joshua Brody, Alana Welm, Djordje Atanackovic

Blood (2021) 138 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2021-154503

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy

Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only